Welcome to our dedicated page for Icon news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on Icon stock.
ICON plc reports developments for a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology companies. Its news commonly covers operating and financial results, clinical trial management activity, net business wins, revenue guidance, and service areas such as patient recruitment, data analytics, laboratory services and regulatory consulting.
Company updates also address partnerships that connect clinical trial technology with research-site systems, expansion of the Accellacare Site Network in therapeutic areas including oncology, and governance or accounting-control matters tied to revenue recognition and financial reporting.
ICON plc (NASDAQ: ICLR), a leading clinical research organization, has announced that its CEO, Dr. Steve Cutler, will present at the William Blair 45th Annual Growth Stock Conference. The presentation is scheduled for Wednesday, June 4, 2025, at 10:40 AM CT. The company will provide updates and links to the live webcast, where available, on the Investor section of their website under the "Events" tab.
ICON (NASDAQ: ICLR) has released its ICON Cares 2024 Report, highlighting significant achievements in environmental, social, and governance (ESG) goals. The company received a 72/100 score from EcoVadis (silver medal) and a B- score on CDP Climate Change response. In 2024, ICON supported over 1,270 clinical studies involving more than 416,000 patients, contributing to 19 medicine approvals.
Notable environmental achievements include exceeding their near-term SBTi target with a 70.06% reduction in Scope 1 & 2 GHG emissions, achieving 84.67% renewable electricity consumption, and reducing laboratory kit wastage by 15-20%. The company expanded its AI and robotic process automation capabilities while strengthening governance protocols.
ICON plc (NASDAQ: ICLR) has released findings from a survey of 155 biotech and pharma professionals regarding multi-indication cardiometabolic R&D for obesity therapies. The survey reveals that 83% of sponsors are pursuing multi-indication approaches in obesity research, but many underestimate the complexity of these strategies.
Key findings show that 90% of respondents are not implementing non-traditional study arms like master protocols, while only 14% pursue multiple indications based on longitudinal data. Furthermore, only 19% follow patients for more than three years. Despite these challenges, 77% of respondents believe multi-indication R&D would lower healthcare costs.
In response, ICON has launched their new Centre for Obesity, featuring an infrastructure of 100 sites and a developing database of 10,000 pre-screened patients across obesity-related comorbidities to facilitate rapid multi-indication research.
ICON reported mixed Q1 2025 financial results with net business wins of $2,022 million and a book-to-bill ratio of 1.01. Revenue decreased 4.3% year-over-year to $2,001.3 million, while adjusted EBITDA was $390.7 million (19.5% of revenue).
Key highlights include:
- Closing backlog of $24.7 billion, up 6.0% from Q1 2024
- GAAP net income of $154.2 million ($1.90 per diluted share)
- Adjusted net income of $258.3 million ($3.19 per diluted share)
- Net debt of $2.9 billion with a net debt to adjusted EBITDA ratio of 1.7x
The company updated its 2025 guidance, now expecting revenue between $7,750-$8,150 million (representing -6.4% to -1.6% YoY) and adjusted EPS of $12.75-$14.25. Performance was impacted by market volatility, customer decision delays, and elevated cancellations. The company repurchased $250 million worth of stock at an average price of $184.
ICON plc (NASDAQ: ICLR) has scheduled its first quarter 2025 earnings release and conference call. The company will release its Q1 2025 financial results after market close on Wednesday, April 30, 2025. A conference call and webcast to discuss the results will be held the following day on Thursday, May 1, 2025 at 8:00am ET. A webcast replay will be available approximately one hour after the call concludes. Any updates or changes to these events will be posted on the Investor section of ICON's website under 'Events'.
ICON (NASDAQ: ICLR) has become the first large Clinical Research Organization to fully integrate Medidata Clinical Data Studio into its clinical workflows. This strategic implementation allows ICON to leverage AI-powered technology for unified data management across Medidata and non-Medidata sources.
The integration enhances ICON's ability to streamline data review, central monitoring, and medical review processes through AI and statistical modeling. This advancement is particularly significant for ICON's Clinical Data Science group, which specializes in risk-based quality management.
The partnership builds on a 20-year relationship between ICON and Medidata, during which they have collaborated on more than 1,700 studies, with over 400 currently active studies across various therapeutic areas including oncology, central nervous system, and vaccine therapies. ICON also utilizes Medidata eCOA and Medidata Designer for clinical operations management.
ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, has announced upcoming presentations at two major healthcare investor conferences. Dr. Steve Cutler, CEO of ICON plc, is scheduled to present at:
- The Leerink Partners Global Healthcare Conference on Wednesday, March 12, 2025, at 8:00 am ET
- The Barclays 27th Annual Global Healthcare Conference on Thursday, March 13, 2025, at 8:30 am ET
Any updates to these events and live webcast links will be available in the Investor section of ICON's website under 'Events'.
ICON plc (NASDAQ: ICLR) and Mural Health Technologies have announced a strategic partnership to implement Mural Link, a comprehensive participant management and payments platform for clinical trials. The collaboration aims to enhance trial participation experience and efficiency.
Through this partnership, ICON will leverage Mural Link's features including:
- Clinical trial participant payment systems
- Tax management capabilities
- Travel and concierge support
- Site-participant communication tools
- Advanced reporting and analytics
A key highlight is Mural Health's fee-free debit card option, designed to eliminate financial barriers to trial participation. The partnership focuses on increasing the recruitable patient population, particularly among historically underrepresented groups, while reducing participant-level operational challenges that contribute to patient attrition.
ICON (ICLR) reported its Q4 and full-year 2024 results, with Q4 net business wins of $2,413 million and a book-to-bill ratio of 1.18. Full-year net business wins reached $9,974 million with a 1.20 book-to-bill ratio. The company's closing backlog grew to $24.7 billion, up 8.3% year-over-year.
Q4 revenue was $2,041.1 million, down 1.2% year-over-year, while full-year revenue increased 2.0% to $8,282 million. Q4 adjusted EBITDA was $422.6 million (20.7% of revenue), and full-year adjusted EBITDA reached $1,735.8 million (21.0% of revenue). The company achieved $1.1 billion in free cash flow for 2024 and maintained a net debt of $2.9 billion.
ICON repurchased $400 million worth of stock in Q4 at an average price of $217 and authorized a new $750 million share repurchase program. The company reaffirmed its 2025 revenue guidance of $8,050-$8,650 million and adjusted EPS guidance of $13.00-$15.00.
ICON plc (NASDAQ: ICLR) announced the expansion of its artificial intelligence (AI) tools portfolio to enhance clinical trial processes. The company has established an AI Centre of Excellence, supported by an AI Governance Committee, to develop and deploy AI solutions.
The new solutions include: iSubmit for automated document management, Mapi Research Trust COA for clinical outcome assessments, FORWARD+ for resource management, Study Start-up Site Contracts for contract drafting, and OMR AI Navigation Assistant for operational metrics analysis.
ICON received an Enterprise Ireland grant to further enhance its AI capabilities. A recent company survey revealed that 13% of biopharma companies face challenges in systematically incorporating AI technologies despite their heavy use in single development programs.